#USA #New York #Securities #Lawsuit #Altimmune

The Gross Law Firm Takes Action for Altimmune, Inc. Shareholders

In a significant move affecting the shareholders of Altimmune, Inc. (NASDAQ: ALT), The Gross Law Firm has announced the filing of a securities class action following a sharp decline in the company's stock price. This action comes after Altimmune's disappointing announcement regarding the results of its Phase 2b MASH trial related to the treatment of MASH (metabolic dysfunction-associated steatotic liver disease).

Context of the Class Action

The class period for this action spans from August 10, 2023, to June 25, 2025, encompassing the period when many Altimmune shareholders purchased their stocks. According to the firm, those who acquired shares during this time are encouraged to connect with them for potential lead plaintiff designation. It's important to note that being appointed as a lead plaintiff is not a prerequisite for participation in any recovery efforts.

On June 26, 2025, Altimmune released a press statement detailing the topline results from its latest clinical trial. Expectations had been high among investors, driven by prior communications from the company. However, the results revealed a critical failure to establish statistical significance in the expected outcomes for fibrosis reduction—one of the primary endpoints in the trial, due in part to an unexpectedly high placebo response.

The Stock Price Plummet

The ramifications of this revelation were immediate and severe. Following the announcement, Altimmune's stock price saw a startling decline, plummeting from $7.71 per share at the close on June 25, 2025, to a mere $3.61 per share by the next trading day—an alarming 53.2% drop in just 24 hours. This significant loss has left many shareholders reeling, prompting the class action filing by The Gross Law Firm to seek justice on behalf of affected investors.

Upcoming Deadlines and Steps for Shareholders

The deadline for shareholders to register for this class action is set for October 6, 2025. Interested parties are encouraged to register without delay to ensure their participation. By doing so, they will be enrolled in a monitoring system that will provide updates throughout the case's progression.

Shareholders should be aware that there is no cost or obligation associated with participation in the class action, and taking this step may help recover losses stemming from the stock's decline. The Gross Law Firm has established itself as a leading class action law firm, with a dedication to protecting the rights of investors who have suffered due to misleading statements or business practices.

Why Choose The Gross Law Firm?

The Gross Law Firm advocates for investors nationwide, focusing on the losses incurred as a result of corporate misconduct. Their commitment extends to ensuring that companies engage in ethical business practices and adhere to legal standards. With extensive experience in managing such cases, The Gross Law Firm aims to recover losses for those impacted by deceit and corporate malpractice.

For shareholders of Altimmune, it is crucial to assess their potential claims swiftly. Participating in this class action could yield positive outcomes following proven instances of inflated expectations and significant financial repercussions.

For more details, shareholders can reach out to The Gross Law Firm directly:

Address: 15 West 38th Street, 12th floor, New York, NY, 10018

Email: [email protected]

Phone: (646) 453-8903